Johnson & Johnson JNJ
272.70 USD -6.00 (-2.15%)
Regular-session close
272.52 -0.18 -0.07%
After hours · Nov 18, 7:45 PM ET
272.58 Day range 278.70
199.96 52-week range 285.75
- YTD
- +31.77%
- 1 year
- +36.35%
News
247wallst.com Invest $25,000 in These 4 Dividend Stocks to Start Building Retirement Income Retirement changes what a portfolio is for. Once the paycheck stops, the number that matters most is how much cash the account sends back each year without pushing a sale of shares.
247wallst.com Here's How Much Passive Income $50,000 Generates in These 4 Dividend Aristocrats Four household-name stocks have raised their dividends for 40 to 70 straight years, yet each one carries a risk that could threaten the streak. Which payout looks safest, and which check is biggest?
fool.com Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic…
fool.com 2 of the Best Dividend Stocks to Buy With $5,000 in November These two dividend stocks offer reliable raises year after year.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to…
fool.com Johnson & Johnson vs. Pfizer: Consistency vs. Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period. Over roughly the last eight…
businesswire.com Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's…
zacks.com J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.
zacks.com J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.
benzinga.com Eli Lilly Short Interest Rises, Remains Below August Peak Eli Lilly and Co. (NYSE:LLY) short sellers added to their positions, with the latest report following the company’s Q3 2026 earnings release.Short interest rose 3.64% to 7.21 million shares as of the…
zacks.com Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
zacks.com Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
247wallst.com Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield…
247wallst.com 3 Bulletproof Passive Income Dividend Kings to Buy and Hold Forever A pending IRS ruling, rising commodity costs, and more test whether the payouts of these passive income Dividend Kings can survive.
fool.com Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Johnson & Johnson currently exhibits a stronger overall position by generating a substantially larger total revenue volume than Novo Nordisk. Johnson & Johnson maintained a consistent…
defenseworld.net 40,053 Johnson & Johnson $JNJ Shares Bought by Banco Santander S.A. Banco Santander S.A. raised its stake in Johnson and Johnson (NYSE: JNJ) by 101.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
defenseworld.net Johnson & Johnson (NYSE:JNJ) Stock Falls 1.1% After Insider Selling Shares of Johnson and Johnson (NYSE: JNJ - Get Free Report) dropped 1.1% on Monday following insider selling activity. The stock traded as low as $282.33 and last traded at $282.6220. Approximately…
benzinga.com Johnson & Johnson Inks $2.2B Deal for Eye Drug Developer Ollin Biosciences Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion upfront and secure $750 million from Blackstone for Phase 3 eye trials.
zacks.com J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold? JNJ's rally reflects stronger earnings and promising drug launches, but MedTech weakness, patent losses and litigation risks remain.
247wallst.com Treasury Yields Just Hit 4.88%, Changing the Math for Dividend Investors A short-term bond fund and a 64-year dividend streak both promise income, but one can shrink when the Fed moves and the other can fall harder in a bad year. Taxes may decide which one actually pays…benzinga.com Blackstone Life Sciences To Provide Johnson & Johnson With $750M In R&D Funding To Support Phase 3 Clinical Development Of OLN324, An Investigational Therapy For Serious Retinal Vascular Diseases Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the…
gurufocus.com Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology Johnson and Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (âOllinâ) a clinical-stage biop
wsj.com Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.benzinga.com Johnson & Johnson Confirms It Will Acquire Ollin Biosciences To Increase Exposure To Serious Eye Disease Treatments For Initial Sum $2.2B And Up To ~$1.125B In Potential Milestones Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., ("Ollin") a clinical-stage biopharmaceutical company developing therapies…
247wallst.com BTAL Buys the Market’s Calmest Stocks and Shorts Its Wildest. It Is Built to Rise When Stocks Fall One little-known fund bets against the market's wildest stocks and can cushion a retiree's portfolio when a selloff hits. But the same design has quietly cost holders during every long rally, and the…
businesswire.com Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage…
defenseworld.net Johnson & Johnson $JNJ Shares Newly Purchased by AlpenGlobal Capital LLC AlpenGlobal Capital LLC acquired a new stake in Johnson and Johnson (NYSE: JNJ) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
247wallst.com 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4% A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that…
247wallst.com 4 Dividend Kings That Kept Raising Payouts Through Recessions and High Interest Rates Four Dividend Kings raised payouts through a financial crisis, zero rates, and the sharpest hikes in decades. Only one yields above 5%, and its thin cash flow makes the next raise the one to watch.
247wallst.com I Bonds Pay 5.51%. Here’s What Dividend Investors Should Know A government-backed bond now out-yields one of the most reliable dividend payers on the market, but the headline number hides a one-year lockup, a rate that resets, and a tax twist. Which income…
247wallst.com 5 Dividend Aristocrats and Kings to Consider if the Stock Market Sells Off Market indicators are flashing red heading into October, and investors who wait too long to reposition may regret it. Five elite dividend stocks in healthcare, consumer staples, and utilities have…
247wallst.com How Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month? The price tag for $3,000 a month in dividends swings by more than a million dollars depending on which stocks you pick. One popular income pick looks cheapest to start and may cost the most by age 79.
defenseworld.net 2,825 Johnson & Johnson $JNJ Shares Sold by Barr E S & Co. Barr E S and Co. lessened its position in Johnson and Johnson (NYSE: JNJ) by 2.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and…
youtube.com The Big 3: JNJ, LLY, AAPL Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks…
zacks.com Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue? Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact…
247wallst.com The S&P 500 Lost 5.9% in a Month, Then Won Back More Than Half in 4 Trading Days. How Much Does a 72-Year-Old Widow Need in Dividend Stocks to Collect $5,000 a Month? A 72-year-old widow inherits her husband's portfolio and wants $5,000 every month from dividends alone. Her $1.6 million sounds like plenty, but the stocks that pay enough come with trade-offs most…
fool.com These 5 Dividend Aristocrats® Have Raised Payouts for Decades Investors worried about market turmoil may want to look at reliable dividend stocks, and these five stand out.
fool.com Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027? Johnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies. Eli Lilly is currently defined by explosive growth in the metabolic…
fool.com Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy? Johnson & Johnson is expertly handling a recent major patent cliff. Recent launches should help boost sales growth over the next few years.
benzinga.com Johnson & Johnson Reports Favorable Data For Bipolar Study Johnson & Johnson reports positive Phase 3 CAPLYTA study data, delivering rapid manic symptom relief for adults with bipolar I disorder.
businesswire.com Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541…
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next…
247wallst.com SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More? One income stream resets every time the Fed moves, while two others depend on a board's vote and a balance sheet. Which payout holds up best over a long retirement, and why might taxes change the…
247wallst.com 3 Legacy Health Care Dividend Stocks That Never Go Out of Style Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by…benzinga.com Johnson & Johnson's Phase 3 Study Evaluating CAPLYTA Met Its Primary And Key Secondary Endpoints CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studiesTwo positive Phase 3…
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com 11 Of 11 Sectors Rise Monday As Growth Leads All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
benzinga.com Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies Johnson & Johnson reported positive Phase 3 ICOTYDE data for psoriatic arthritis and new nipocalimab results at ACR Convergence 2026.benzinga.com Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16 Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an…
